Alere also said that some of its creditors have agreed to waive defaults arising from its delay in filing its 2015 earnings report, though others have already filed default notices.
The company said its financial plan contemplates the acquisition of both St. Jude and Alere, which is under investigation for its foreign business practices.
The companion test will let doctors identify the best treatment for CLL patients with 17p deletions, a subset that has historically lacked therapeutic options.
The test, which was previously approved for CLL prognosis, is now cleared for use in identifying patients who may benefit from AbbVie and Genentech's Venclexta.
Abbott Molecular has been building a PCR-based system from the ground up and plans to sell it in parallel with the m2000, eventually replacing that system.
